Skip to content
Acting Auditions – Lifestyle
Author:
Karyopharm Therapeutics Inc.
Karyopharm Announces FDA Acceptance of Supplemental New Drug Application for XPOVIO® (selinexor) Plus Ruxolitinib for the Treatment of Patients with Myelofibrosis
November 17, 2026
Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future
November 2, 2026